Dr. Sadeghi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Ste 8302E
Los Angeles, CA 90089Phone+1 323-865-3000Fax+1 323-865-0061
Summary
- Dr. Sarmad Sadeghi earned his medical degree at Tehran University of Medical Sciences. He has a Master of Science degree (MS) in Health Information Sciences and a Doctor of Philosophy degree (PhD) in Public Health Management and Policy Sciences from the University of Texas Health Sciences Center at Houston.
He completed his internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation. He completed his hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. Dr. Sadeghi joined the faculty at the division of oncology of University of Southern California in 2013 and has a clinical and research focus in genitourinary malignancies, specifically bladder, kidney and prostate cancers.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2006 - 2008- University of Texas Health Science Center at HoustonResidency, Surgery, 2003 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2012 - 2025
OH State Medical License 2008 - 2014- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Start of enrollment: 2014 Dec 11
- Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Start of enrollment: 2016 Nov 21
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2017 Jul 19
Publications & Presentations
PubMed
- 8 citationsProstatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer.Afsaneh Barzi, Eric A. Klein, Tanya B. Dorff, David I. Quinn, Sarmad Sadeghi
Prostate Cancer and Prostatic Diseases. 2016-03-01 - 7 citationsEphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.Sarmad Sadeghi, David Quinn, Tanya Dorff, Sumanta Pal, Susan Groshen
Journal of Clinical Oncology. 2023-01-20 - 21 citationsCessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.Sarmad Sadeghi, Laurence Albiges, Laura S. Wood, Shari L. Black, Timothy D. Gilligan
Cancer. 2012-07-01
Press Mentions
Colorectal Cancer Screening Uptake Tripled in 45-49 Age GroupOctober 3rd, 2024- Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad SadeghiOctober 17th, 2022
Higher Facility Caseloads Associated with Longer OS After Prostatectomy for Prostate CancerAugust 27th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
